|
gptkbp:instance_of
|
gptkb:healthcare_organization
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Leishmania_spp.
gptkb:Trypanosomatida
gptkb:Trypanosomatidae
gptkb:Leishmania
|
|
gptkbp:associated_with
|
gptkb:HIV/_AIDS
malnutrition
immunosuppression
|
|
gptkbp:caused_by
|
gptkb:Leishmania_parasites
|
|
gptkbp:complications
|
disfigurement
secondary bacterial infections
psychosocial impact
|
|
gptkbp:coordinates
|
gptkb:Lutzomyia_sandflies
gptkb:Phlebotomus_sandflies
|
|
gptkbp:distribution
|
tropical regions
subtropical regions
|
|
gptkbp:duration
|
weeks to months
|
|
gptkbp:end_of_life
|
low
|
|
gptkbp:first_described_by
|
1900s
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cutaneous leishmaniasis
|
|
gptkbp:incubation_period
|
weeks to months
|
|
gptkbp:is_often_used_in
|
gptkb:Middle_East
gptkb:North_Africa
gptkb:South_America
gptkb:Southeast_Asia
|
|
gptkbp:is_popular_in
|
estimated 1.5 million cases annually
|
|
gptkbp:is_protected_by
|
gptkb:mythological_figure
vector control
bed nets
|
|
gptkbp:is_vulnerable_to
|
ongoing research
|
|
gptkbp:related_to
|
mucocutaneous leishmaniasis
visceral leishmaniasis
|
|
gptkbp:research_focus
|
treatment efficacy
epidemiological studies
immunology
vector control strategies
|
|
gptkbp:risk_factor
|
climate change
deforestation
urbanization
poor housing conditions
|
|
gptkbp:scientific_classification
|
neglected tropical disease
|
|
gptkbp:social_responsibility
|
serological tests
PCR testing
skin biopsy
culture of lesions
endemic in 88 countries
|
|
gptkbp:symptoms
|
scarring
ulcers
skin sores
|
|
gptkbp:transmission
|
sandfly bites
|
|
gptkbp:treatment
|
gptkb:miltefosine
liposomal amphotericin B
antimonial compounds
|